KYMR
$77.91-1.66 (-2.09%)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Recent News
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026
Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the most promising stocks under $100 to buy. On March 10, Kymera Therapeutics announced that data from its Phase 1b clinical trial of KT-621 will be featured in a late-breaking oral presentation at the American Academy of Dermatology 2026 Annual Meeting. The study, known as the BroADen trial, […]
Nextech Trims Kymera at a Recent High — think Foolishly before acting.
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside
Kymera Therapeutics has begun first in human clinical trials of an IRF5 directed therapy, a new approach to targeting immune driven disease. The company has also advanced KT-621, its lead oral STAT6 degrader, with early data suggesting potential to rival or surpass a key existing therapy. These milestones highlight progress in Kymera Therapeutics' immunology pipeline at a time when interest in protein degradation platforms remains high. Kymera Therapeutics (NasdaqGM:KYMR) is drawing...
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic. That is not a minor pipeline update. Kymera Therapeutics missed on both revenue and earnings in Q4. Revenue ... Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.